Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis
Inturlekin 33 in Ankylosing Spondylitis Patients and Its Relationship to Subclinical Atherosclerosis
1 other identifier
observational
45
0 countries
N/A
Brief Summary
detect level of Inturlekin 33 in ankylosing spondyilits patient measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients detect the relation between IL33 and subclinical atherosclerosis in Ankylosinig Spondylitis patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2024
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 19, 2024
CompletedFirst Posted
Study publicly available on registry
August 21, 2024
CompletedStudy Start
First participant enrolled
September 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
August 22, 2024
August 1, 2024
1.9 years
August 19, 2024
August 20, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
detect level of IL33 in AS patients
measure level of IL33 in the serum of AS patients measure caroid intima media thickness CIMT in AS patients
3 years
Secondary Outcomes (1)
detect the reation between IL33 and subclinical atherosclerosis in AS patients
3 years
Study Arms (2)
ankylosing spondylities patients
detect level of IL33 in serum of AS patients measure carotid intima media thickness by caroid dupex
control persons
detect level of IL33 in serum of normal control group measure carotid intima media thickness by caroid dupex
Interventions
measure Carotid intima media thickness
Eligibility Criteria
* patient diagnosed as Ankylosing Spondylitis according to ASAS 2009 * Age (20-40)
You may qualify if:
- patient diagnosed as Ankylosing Spondylitis
- Age (20-40)
You may not qualify if:
- Patients with other rheumatic diseases/other SPA types
- Participants with history of CVD event in past or present
- Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
- Patient with other risk factor for atherosclerosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Li GX, Wang S, Duan ZH, Zeng Z, Pan FM. Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol. 2013;42(3):226-31. doi: 10.3109/03009742.2012.735700. Epub 2013 Feb 15.
PMID: 23409750RESULT
Biospecimen
blood sample
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principial investigator
Study Record Dates
First Submitted
August 19, 2024
First Posted
August 21, 2024
Study Start
September 1, 2024
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
August 22, 2024
Record last verified: 2024-08